comparative efficacy
head-to-head data, mechanism differences, and clinical selection factors
comparative efficacy
semaglutide does not exist in isolation. tirzepatide, the dual GIP/GLP-1 agonist, has shown greater weight loss in head-to-head trials. liraglutide, the first-generation daily GLP-1 agonist, remains widely prescribed with a longer safety track record. this unit compares mechanism differences, clinical trial results across weight loss and glycemic endpoints, cardiovascular outcome data, and the practical factors that drive selection between agents.
the paid sections break down the SURMOUNT-5 head-to-head (tirzepatide's ~47% greater weight loss), the liraglutide mechanism and tolerability contrast, the full GLP-1RA class on a single efficacy/safety matrix, and a decision framework for when semaglutide still wins on cardiovascular, renal, or oral-route criteria.
Interactive Visualization
compare GLP-1 agonists across efficacy, safety, cost, and convenience dimensions.